Related Experiment Videos
[Incidental kidney neoplasm: anatomopathologic characteristics and clinical behavior]
Summary
Kidney tumors found incidentally during imaging for other conditions have a better survival rate. These incidentalomas are often smaller and detected at an earlier stage than symptomatic kidney tumors.
Area of Science:
- Urology
- Oncology
- Radiology
Background:
- Increased use of abdominal ultrasound and CT scans leads to more incidental kidney tumor discoveries.
- Kidney tumors are increasingly found by chance during imaging for non-renal conditions.
- Understanding the characteristics and outcomes of incidentally discovered kidney tumors is crucial.
Purpose of the Study:
- To compare anatomopathological features of incidentally discovered kidney tumors (incidentalomas) versus symptomatic kidney tumors.
- To evaluate the clinical evolution and overall survival rates between these two groups.
- To determine if incidental discovery impacts patient prognosis.
Main Methods:
- Retrospective analysis of 338 patients who underwent radical nephrectomy between 1979 and 1999.
- Patients were divided into two groups: symptomatic tumors (Group 1) and incidentalomas (Group 2).
- Key parameters analyzed included histological type, pathological stage, Fuhrman's grade, tumor diameter, and overall survival.
Main Results:
- Incidentalomas (Group 2) showed a higher incidence of stage T1 tumors (42.1%) compared to symptomatic tumors (Group 1) (29.4%).
- Advanced tumor stages were more frequent in the symptomatic group (15.6%) than in the incidentaloma group (9%).
- Patients with incidentalomas had significantly longer overall survival (13.5% deaths) compared to symptomatic patients (23.1% deaths) (p < 0.03).
Conclusions:
- Kidney tumors discovered incidentally are associated with significantly better overall survival.
- This improved survival is attributed to incidentalomas being detected at an earlier pathological stage and smaller size.
- Routine imaging for non-renal conditions aids in early detection and improved outcomes for kidney cancer patients.